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Despite remarkable medical development, chronic infectious diseases caused by the infections with persistent pathogens such as hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and mycobacterium tuberculosis (M.tb), have not been conquered yet. During the chronic infection, the interaction between host and chronic pathogen often fosters immune suppressive environment. Such environment leads to the exhaustion of pathogen-specific T cells, resulting in the failure to the eradication of pathogen but the success to the protection of host from immunopathological damage. Finally, host and pathogen ensure the reduction of host immunopathology but the extension of pathogen persistence.
Under the persistence of pathogens, effector T (T eff ) cells lose progressively their effector function such as cytokine production and proliferative potential and finally become exhausted T (T exh ) cells. T-cell exhaustion can be caused by various factors including immune checkpoints, cytokines, regulatory T (T reg ) cells, and altered antigen presenting cells (APCs) [1] . Immune inhibitory receptors, also known as immune checkpoints, such as programmed death-1 (PD-1), T-cell immunoglobulin mucin 3 (TIM-3), cytotoxic T lymphocyte antigen-4 (CTLA-4), and lymphocyte activation gene-3 (LAG-3) are expressed on T eff cells by T-cell receptor (TCR) stimulation and their expressions are maintained or even increased by repeated TCR stimulation during chronic infection. Upon ligands binding, such checkpoints are triggered to transmit inhibitory signal into T eff cells by alone or their combination, which leads to the generation of T exh cells and the attenuation of T-cell-mediated immunopathology. The interaction of PD-1 and its ligand, PD-L1, has been known to play a critical role in the exhaustion of T eff cells. The role of PD-1 during chronic pathogen infection in suppressing T-cell function was demonstrated in the mouse model chronically infected with lymphocytic choriomeningitis virus (LCMV) [2] . This study showed that blockade of PD-1:PD-L1 interaction during chronic LCMV infection controlled viremia by restoring the function of virusspecific T exh cells. More specifically, only PD-1 + CD8 + T cells, but not PD-1 -CD8 + T cells, regained their function upon PD-1:PD-L1 blockade, indicating that the effect of PD-1 on T-cell exhaustion is T-cell-intrinsic ( Figure 1 ). Another interesting point was that PD-L1-deficient mice succumbed to chronic LCMV infection, resulting in death of mice within one week post-infection. PD-1:PD-L1 pathway seemed to be also critical in protecting mice from persistent bacterial infection because PD-1-deficient mice were extraordinarily sensitive to tuberculosis [3] . These data strongly suggests that PD-1:PD-L1 pathway regulates immune-mediated tissue damage during persistent infection by paralyzing the pathogen-specific T cells.
The claim that PD-1 expressed by T cells is a culprit of T-cell exhaustion is now generally accepted but there can be another causing factors. One of the candidates is T reg cells, which play an important role for maintaining immunological self-tolerance and controlling T-cell-mediated autoreactive T-cell attack on tissue, because a number of studies showed the increase of T reg cell population during persistent viral, helminthic, and bacterial infections. Depletion of T reg cells in the mice chronically infected with LCMV was reported to strikingly expand functional LCMV-specific CD8 + T cells, [7] . Taken together, albeit such a complexity, it is evident that T reg cells can contribute to the inhibition of T-cell response and the protection of tissue from T-cell-mediated pathology.
Editorial
In spite of the observation that PD-1 is upregulated on T reg cells during chronic infection, it is less known about the role of PD-1 expressed by T reg cells. We recently found that PD-1 hi T reg cells generated during chronic LCMV infection displayed much stronger suppressive activity than PD-1 lo T reg cells present in steady state [6] . Either PD-1 blockade on PD-1 hi T reg cells or PD-L1 deficiency on T eff cells dramatically ablated T reg cell-mediated suppression of T eff cell immune response, demonstrating the necessity of PD-1 on T reg cells and PD-L1 on T eff cells. These results highlight a critical role of PD-1:PD-L1 interaction between T reg cells and PD-L1 on T eff cells and define PD-1 upregulated on T reg cells as a prerequisite for T reg cell-mediated strong suppression (Figure 1 ). It should be further investigated for the molecular mechanism by which whether a ligation of PD-L1 in T eff cells onto PD-1 hi T reg cells triggers PD-1 signal in T reg cells or a reverse signal via PD-L1 in T eff cells upon a ligation of PD-1 provided by T reg cells inhibits T eff cell function. If the former is applied in vivo, PD-L1 is probably provided by pathogen-infected APCs as well as T eff cells. Regarding cell-specific expression of PD-1, our results propose that PD-1 expressed by T reg cells, in addition to that by T exh cells, contributes to the functional suppression of T eff cells and subsequent attenuation of immunopathology ( Figure  1) .
Collectively, PD-1:PD-L1 interaction is a major strategy for the suppression of T eff cell-mediated immune response during chronic pathogen infection. Meanwhile, in regard to the immunopathological damage, PD-1:PD-L1 interaction protects T eff cell-mediated tissue damage in the host. Of importance, PD-1:PD-L1 interaction is capable to occur in between T reg cells and T eff cells, in addition to between T eff cells and pathogen-infected cells. In both case, T eff cells become exhausted via direct interaction with separate partners and eventually fail to not only eradicate pathogens but also induce immunopathology in the host. Lastly, these studies provide perspectives regarding the practical and clinical treatment strategies for chronic infectious disease. Blockade of PD-1:PD-L1 can be useful to treat efficiently chronic virus infection but its potential risk for immunopathologic damage needs to be carefully monitored.
